Detection of MCP-4/CCL13 Isoforms in Serum
Author Information
Author(s): Leonardo Rossi, Ramy Moharram, Brian M Martin, Richard L White, Monica C Panelli
Primary Institution: Department of Human Morphology and Applied Biology, University of Pisa
Hypothesis
The study aims to characterize MCP-4/CCL13 isoforms in the serum of RCC patients undergoing high-dose IL-2 immunotherapy.
Conclusion
The study successfully identified two different isoforms of human MCP-4/CCL13 in the peripheral blood for the first time.
Supporting Evidence
- MCP-4/CCL13 is a major chemoattractant for eosinophils and other immune cells.
- The study detected two isoforms of MCP-4/CCL13 in serum samples.
- The isoforms were identified using SELDI-TOF-MS technology.
Takeaway
Researchers found two types of a protein called MCP-4/CCL13 in the blood of patients receiving a specific cancer treatment.
Methodology
The study used SELDI immunoaffinity capture technology to analyze serum samples from patients.
Limitations
The study's assessment of MCP-4/CCL13 isoforms was purely qualitative, and differential quantification between pre and post treatment samples was not consistent.
Participant Demographics
Patients with metastatic renal cell carcinoma (RCC) undergoing high-dose IL-2 treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website